| Filed On | Filing |
|---|---|
| 06 Oct 2026 | SCHEDULE 13G |
| 01 Oct 2026 |
Form 4: Xanthopoulos Kleanthis Gabriel, Director
Received 5,000 shares as a grant or award |
| 01 Oct 2026 |
Form 4: Liu Jean I, Director
Received 8,984 shares as a grant or award |
| 30 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 01 Jul 2026 |
Form 4: Xanthopoulos Kleanthis Gabriel, Director
Received 3,738 shares as a grant or award |
| 01 Jul 2026 |
Form 4: Liu Jean I, Director
Received 6,718 shares as a grant or award |
| 02 Jun 2026 |
Form 4: Huang James, Director
Bought 150,000 shares ($372K) |
| 01 Jun 2026 | EFFECT |
| 28 May 2026 | CORRESP |
| 22 May 2026 | UPLOAD |
| 15 May 2026 | SCHEDULE 13G/A |
| 15 May 2026 | F-3 |
| 12 May 2026 | 10-Q |
| 12 May 2026 | 8-K: Results of Operations and Financial Condition |
| 23 Apr 2026 | 8-K: Regulation FD Disclosure; Other Events |
Loading...
